Merck & Co., Inc. (MRK)
Merck's LOE Risks Mitigated - R&D And M&As Are Paying Off
Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges related to two recent acquisitions. Their in-house capabilities remain excellent, with the patient transition to KEYTRUDA QLEX working out as expected, aided by the US FDA approval for Idvynso with double digits billion revenue opportunities. Combined with the aggressive M&A activities, MRK is likely to deliver their mid-2030s revenue guidance of over $70B despite KEYTRUDA's upcoming patent cliff.
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Transcript
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Transcript
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View Tightened
Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
Merck MRK is set to report its first-quarter 2026 earnings on April 30, before market open. The Zacks Consensus Estimate for first-quarter top line is pegged at $15.90 billion, while the same for the bottom line stands at a loss of $1.51 per share.
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
Merck: Bullish Setup Into Q1 Earnings
Merck & Co., Inc. will publish its first-quarter figures at the end of April. I again expect strong performance from Keytruda and Winrevair. However, in the report itself, I believe the defining moment will be MRK's sales of Keytruda Qlex, whose main role is to offset the launch of biosimilars to Keytruda from 2028.
